FDA Rejects Regeneron's Eylea HD
Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.
The US Food and Drug Administration (FDA) has rejected a prefilled syringe version of Regeneron’s ophthalmology blockbuster Eylea HD (aflibercept), due to manufacturing shortcomings.
The FDA issued a complete response (CR) letter for Eylea HD’s pre-filled syringe supplemental biologics licence application (sBLA) citing unresolved issues at a facility of its manufacturing partner, Novo Nordisk.
The sole reason for the rejection was unresolved issues at a facility of its manufacturing partner, Novo Nordisk.
The FDA uncovered problems during an inspection of Novo Nordisk’s filling plant in Bloomington, Indiana, reported by Regeneron in August 2025.
Author's summary: FDA rejects Eylea HD due to manufacturing issues.
More News
- GRIDLOCK Definition & Meaning
- Tartan Army set for ‘big bash’ in Boston with two games in New England
- Another Coup In Africa, Soldiers Appear On State TV To Announce Takeover
- Benin coup attempt foiled by loyalist troops, interior minister says
- Flight Booking, Cheap Flights, Air Tickets at Lowest Fare
- No quick fix for ‘tiresome’ M50 gridlock, Minister says
- Attempted coup d'état in Benin
- Hundreds stranded after IndiGo canceled 1,000 flights in India air travel chaos
- Cheap Domestic Flights in United States of America
- Heavy rain gridlocks KL traffic